University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:

Slides:



Advertisements
Similar presentations
Common/shared responsibilities between jobs.
Advertisements

Human Rights and Palliative Care: A Primer Kiera Hepford Open Society Foundations Costing for Change Seminar Brasov, Romania October 26 th - 28 th, 2011.
Country Report for: ALBANIA DR. KRISTO HUTA. 2 Demographic Dat a Albania: Population Albania: Population »Year 1990: inhabitants. »Year 1990:
1 Potential & Actual Opioid Diversion in Vietnam, Methods of Preventing Diversion, and Barriers to “Balance” Eric Krakauer, MD, PhD Harvard Medical School.
MaineCare’s New Medication Assisted Treatment (MAT)/Methadone Maintenance Therapy (MMT) Policy Kevin S. Flanigan, MD Medical Director Office of MaineCare.
What factors from the outside environment do you think will be important to AMDA’s future success?  Movement to evidence-based medicine  Emerging models.
PSK Annual Conference 2008 Palliative care medicine: A balanced approach to opioid availability and safe use in Kenya Presenter: Dr. Bilha Kiama-Murage.
Action Plan India Priya, Nandini, Shalini, Dr. Sudhir, Rajesh, Raj, Frank, David.
The Estimation of National Opioid Requirements: New INCB/WHO Guidelines International Pain Policy Fellowship Training Session Madison, Wisconsin, USA 8.
Hospital Pharmacy Payam Parchamazad, PharmD Staff Pharmacist
MaineCare & Opioid Treatment Where we are… How we got here… Where we are going… Kevin S. Flanigan, MD Medical Director Office of MaineCare Services.
Clinical Pharmacy Basma Y. Kentab MSc..
Perspectives of Former International Pain Policy Fellows International Pain Policy Fellowship Training Program Madison, Wisconsin, USA 6 August 2012 Bishnu.
Development of a Road Map to Controlled Substance Diversion Prevention Rene Cronquist, RN, J.D. Director of Practice and Policy Minnesota Board of Nursing.
Clinical pharmacy Dr. Mohammed Al-Rekabi Lecture One First Semester.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Cohort III International.
Situation analysis in Kyrgyzstan Making Opioids Available in Eastern Europe and Central Asia March 5-6, 2013 Vienna.
Training of Process Facilitators Training of Process Facilitators.
Research Activities to Document Progress During IPPF Aaron M. Gilson, MS, MSSW, PhD Research Program Manager/Senior Scientist Pain & Policy Studies Group.
DON’T FORGET THE ‘E’ IN “MORPHINE” International Pain Policy Fellowship: Advocacy & Communications.
Dr Samira Alsenany.  Knowledge must be translated into clinical practice to improve patient care and outcomes  The understanding of care based on evidence.
Country Report for: UKRAINE Natallia Datsiuk, MPH Bogomolets National Medical University Ukraine, Kyiv.
Local Public Health System Assessment using the NPHPSP Local Instrument Essential Service 6 Enforce Laws and Regulations that Protect Health and Ensure.
Clinical Pharmacy Part 2
Steps for Success in EHR Planning Bill French, VP eHealth Strategies Wisconsin Office of Rural Health HIT Implementation Workshop Stevens Point, WI August.
For Pharmacy Tech Training. Goal 1 Assist the pharmacist in collecting, organizing and evaluating information for direct patient care, medication use.
Understanding and Using INCB Opioid Consumption Statistics: Including Morphine Equivalence 8 August 2012 Martha Maurer, MSW, MPH, PhD Pain & Policy Studies.
For Pain or Not for Pain: Methadone Madness
Current System of Drug Control In Georgia Prof. D. Kordzaia – Georgian National Association for Palliative Care VIENNA - March 5-6, 2013 “Making Oral Opioids.
“Improving opioid availability through advocacy” Experience from Serbia Snežana Bošnjak International Pain Policy Fellow ( ) Institute for Oncology.
Ministry of Health of the Republic of Armenia Feb 2013.
WHO Access to Controlled Medications Programme & Ensuring balance in national policies on controlled substances Barbara Milani, Technical Officer Department.
Overviews of the Drug Distribution System & Barriers to Opioid Availability Dr. Bishnu Dutta Paudel International Pain Policy Fellowship Training Program.
Description of the current system of drug control in Romania Prof. Daniela Mosoiu, MD, PhD Hospice Casa Sperantei Brasov, Romania.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Country Report for:
Medicines and Service Availability and Accessibility in Cancer Care in Georgia 28 th August 2012 Tbilisi Tamari Rukhadze MD. PhD. Oncologist, International.
Implementation of the Substitution Maintenance Therapy in the framework of the Programme “Overcoming HIV/AIDS Epidemics in Ukraine” Stakeholders meeting.
ACCESS TO MEDICINES - POLICY AND ISSUES
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for:
Methods to Evaluate and Improve National Policy: Focus on 2011 WHO Guidelines and PPSG Global Policy Evaluation Aaron M. Gilson, MS, MSSW, PhD Research.
“” “Balance” Jim Cleary, MD Associate Professor of Medicine Director, Palliative Care Medicine, UW Hospital & Clinics Director, WHO Collaborating Center.
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
Single Convention on Narcotic Drugs Establishes a regulatory system for narcotic drugs government authorization is required for participation in the trade.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
Texas State Board of Medical Examiners Bruce A. Levy, M.D., J.D.
 the study of the rightness or wrongness of human conduct.  In any situation involving two or more individuals, values may come into conflict and ethical.
Ensuring Availability and Preventing Diversion International Pain Policy Fellowship August 7, 2012 David E. Joranson University of Wisconsin Pain & Policy.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Cohort III International.
"Perspectives of former International Pain Policy Fellows" Prof. Snežana Bošnjak, MD, PhD Institute for Oncology and Radiology of Serbia (IORS) Belgrade,
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Cohort III International.
Using drug use evaluation (DUE) to optimise analgesic prescribing in emergency departments (EDs) Karen Kaye, Susie Welch. NSW Therapeutic Advisory Group*
National Public Health Performance Standards Local Assessment Instrument Essential Service:6 Enforce Laws and Regulations that Protect Health and Ensure.
Preventing drug diversion: Principles and concepts International Pain Policy Fellowship August 7, 2012 David E. Joranson Distinguished Scientist, Founder.
University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Cohort III International.
Bulgarian National Hepatitis Plan and Compassionate Use Regulations Dr. Stanimir Hasardzhiev Executive Director, ELPA Chairperson, Hepasist REPUBLIC OF.
Standards and Competencies for Cancer Chemotherapy Nursing Practice in Canada: CANO/ACIO AN INTRODUCTION.
To Audit – A Pharmacist Independent Prescribers Experience where did I start? Non Medical Prescribers Conference 2012 Graham Rodgers Pharmacist IP.
Prepared by: Imon Rahman Lecturer Department of Pharmacy BRAC University.
 Pharmaceutical Care is a patient-centered, outcomes oriented pharmacy practice that requires the pharmacist to work in concert with the patient and.
Introduction to Clinical Pharmacy
Indispensable, adequately provided and not unduly restricted
Prescription Drug Monitoring Program
Implementing Direct Payment for Clinical Pharmacy Services
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Essential Drugs and Medicines Policy
Impact of Policy and Regulatory Responses to the Opioid Epidemic on the Care of People with Serious Illness Hemi Tewarson, Director, Health Division National.
Background Cancers are among the leading causes of morbidity and mortality worldwide, responsible for 18.1 million new cases and 9.6 million deaths in.
Prescription Drug Monitoring Program
Essential Drugs and Medicines Policy
Situation analysis in Kyrgyzstan
Presentation transcript:

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care Action Plan for: ALBANIA Prepared by: Kristo Huta Sokol Morina Snezana Bosnjak Jody Moen 10 August 2012

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care 1: State the 3-5 problems that lead to inadequate patient access to opioid analgesics – Be as specific as you can Problem 1: Problem 2: Problem 3: Unavailability of IR morphine and low range of doses of SR morphine Lack of knowledge and negative attitudes about opioids Unbalanced policies exist for prescribing, dispensing and reimbursement.

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care A: State the problem that leads to inadequate patient access to opioid analgesics (What?) – Be as specific as you can in stating one problem Unbalanced policies exist for prescribing, dispensing and reimbursement. –Limits to duration of therapy per prescription (7 days) –The amount of money allocated medications restricts the number or amount of prescriptions to patients, consequently creating a barrier to treatment –Limits to diagnosis/stage of disease: only cancer patients in the terminal phase can receive opioids (HIV/AIDS are excluded) –Restrictions to maximum daily dose of morphine that may be prescribed by a GP(100 mg/day) –Restricted authority to prescribe opioids to specifically licensed physicians –Few pharmacies stock opioids(only one per region) a special license is required to dispense opioids Cost-related factors Fear of theft / diversion –The range of reimbursed opioids is limited (Tramadol, transdermal Fentanyl, Methadone not reimbursed) PROBLEM 1

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care 1.To amend the law and change the regulations in accordance with the principle of balance 2.Achieve access to cancer pain management for patients regardless of the stage of their disease 3.Negotiate with the Health Insurance Fund to increase the reimbursement allocation to physicians, thereby educating them on the need 4.Negotiate with the MOH to increase the number of pharmacies that dispense opioids B: State the objective(s) that would address the problem. Which objectives are the top priorities? (What?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care C: What action steps are needed to achieve the objectives? (How?) –Based on the National Cancer Control Program and the Palliative Care Strategy, the Palliative Care working group will: propose to the MOH to amend the law from 7 up to 28 days in treatment duration propose to the MOH to change the regulation to allow opioid prescription for non cancer patients with moderate to severe pain propose to the Health Insurance Institute to remove the limit daily dose of morphine that may be prescribed propose to the MOH to increase the number of physicians allowed to acquire a license to prescribe (after appropriate education and training in effective and safe prescribing) Implement a survey to pharmacists regarding their knowledge and attitudes on stocking opioids, collect the results, and then share them with the MoH (No need to create a survey! Use the one prepared by PPSG, Aaron proposed that in the discussion) Jody will share this propose to the MOH an increase in the number of licensed pharmacies and then obligate those pharmacies to dispense opioids.(one in each town) propose to the Health Insurance Fund to cover the cost of morphine as an Essential WHO medication,with reference to pain relief as a human rights issue (provide 2008 Letter to CND from Special UN Rapporteurs) 1.Palliative Care working group 2.MOH – Directory of Pharmacy 3.Health Insurance Institute 4.Pharmacy Association 5.IPPF mentors 6.Members of Health Parliamentary Commission 7.PPSG for survey for pharmacists D: List those who have the authority and/or responsibility to take the necessary action; and with whom they should collaborate. (Who?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care E: Timeline for completion of action steps. (When?) 1.One year (end of August 2014) 1.Attendance of IPPF mentor Stephen Connor at meetings with MoH and HII (pending financial support) 2.Collaboration with Chief of Oncology Dept in University Center in Tirana 3.Local WHO representative 4.Resources from PPSG and IEC 5.Commitment from Palliative Care working group 6.Seek funds from SOROS, to implement objectives F: What assistance (technical, financial) will be needed to achieve each objective under part “B”? (How much?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care 1.Survey to pharmacies and results 2.Letters and proposals to MoH, HII, and pharmacies 3.Report summaries from each meeting 4.Parliament passes the law G: Expected outputs, and how measured

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care A: State the problem that leads to inadequate patient access to opioid analgesics (What?) – Be as specific as you can in stating one problem 1.Unavailability of IR morphine and low range of doses of SR morphine –Only 10mg SR morphine is available, 30mg and 60mg SR morphine are needed PROBLEM 2

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care 1.Register 10 mg IR Morphine 2.Register 30mg and 60mg SR Morphine B: State the objective(s) that would address the problem. Which objectives are the top priorities? (What?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care C: What action steps are needed to achieve the objectives? (How?) 1.Inform decision-makers that oral IR Morphine is indispensable for treatment of cancer pain 2.Raise interest Albtrade Pharma company to register IR Morphine and other dosage forms of SR Morphine 3.Explore options to import morphine tablets 4.Calculate the need for IR and SR Morphine for a 3-year time period 1.MOH 2.Pharmaceutical company (Albtrade Pharma) 3.Drug Control Agency 4.Health Insurance Institute 5.Local WHO office 6.Members of Health Parliamentary Commission 7.Addiction office D: List those who have the authority and/or responsibility to take the necessary action; and with whom they should collaborate. (Who?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care E: Timeline for completion of action steps. (When?) 1.2 years 1.Collaboration with International Expert – IPPF mentor Stephen Connor 2.Advice from Martha Maurer in how to calculate estimate 3.Palliative Care working group 4.Sign and use Morphine Manifesto as an advocacy tool (PC members) 5.Working group of Palliative Care new law F: What assistance (technical, financial) will be needed to achieve each objective under part “B”? (How much?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care 1.Oral IR and SR morphine available and accessible for cancer pain and palliative care 2.Calculation of the need for oral morphine for cancer pain treatment 3.Calculation of the need for IR and SR morphine 4.Report to the MOH about the need for IR and SR (30mg and 60mg) based on the WHO Essential Medicines list. G: Expected outputs, and how measured

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care A: State the problem that leads to inadequate patient access to opioid analgesics (What?) – Be as specific as you can in stating one problem 1.Lack of knowledge and negative attitudes among health care professionals about opioids. PROBLEM 3

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care 1.Educate health care professionals about the indispensability, efficacy and safety of morphine for moderate and severe cancer pain and palliative care 2.Change negative/wrong attitudes 3.Educate pharmacies on the obligation to ensure adequate availability of opioids B: State the objective(s) that would address the problem. Which objectives are the top priorities? (What?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care C: What action steps are needed to achieve the objectives? (How?) 1.Translate and adapt international clinical practice guidelines (CPGs) on cancer pain management in collaboration with QKSCA 2.Organize and conduct lectures, professional meetings, round table discussions, etc on cancer pain management and palliative care 3.Disseminate translated guidelines to health care professionals at the above-mentioned events 4.Prepare pre- and post-tests to evaluate knowledge acquired 5.To present to guidelines to all stakeholders 1.MoH (pharmaceutical dept. and drug issues dept.) 2.Health Insurance Institute 3.Palliative Care working group 4.GPs 5.Oncology associations 6.Albanian Association for Pain 7.Albanian Association for Palliative Care 8.Potential funding organizations 9.Members of Health Parliamentary Commission D: List those who have the authority and/or responsibility to take the necessary action; and with whom they should collaborate. (Who?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care E: Timeline for completion of action steps. (When?) 1.Ongoing throughout 2 year period 1.Translation services 2.Publication costs 3.Dissemination costs 4.Cost of meeting,workshops, round tables F: What assistance (technical, financial) will be needed to achieve each objective under part “B”? (How much?)

University of Wisconsin Pain & Policy Studies Group World Health Organization Collaborating Center for Pain Policy and Palliative Care 1.Translated/published guideline 2.Prepared slide presentations from various meetings, lectures, discussions, etc 3.Number of meetings 4.Number of meeting participants 5.Pre- and post-test results G: Expected outputs, and how measured